loading of all patients was 2.01 AE 1.64, with the highest and lowest loadings noted in Japan (4.13 AE 3. 13) and Indonesia (1.16 AE 0.68), respectively.
Conclusion: Differences in psychiatrist training as well as the civil culture and health insurance system of each country may have contributed to the differences in these rates. The concept of drug loading can be applied to other medical fields.
T HE TERM POLYPHARMACY was originally coined to refer to problems related to multiple drug consumption and excessive drug use during treatment of a disease or disorder. 1 In the treatment of schizophrenia, 'polypharmacy' usually refers to the simultaneous use of two or more antipsychotic medications, and 'combined (adjunct) medications' as the use of mood stabilizers, antidepressants, anxiolytics, or hypnotics in addition to single or multiple antipsychotics. Ideally, a clinician should administer monotherapy of an antipsychotic to treat schizophrenia; however, some proportions of patients respond to this treatment suboptimally. 2 Thus, polypharmacy and combined medications are frequently applied in clinical practice. The prevalence of polypharmacy varies among countries: It is lower in North American countries (such as the USA [3] [4] [5] and Canada) 6 and Europe (such as the UK) 7 but higher in Asian countries (such as Japan and Singapore) 8, 9 . As it is expensive with unproven efficacy and several side-effects, the use of antipsychotic polypharmacy used to be discouraged and avoided. 10 However, recent data have suggested that antipsychotic polypharmacy and combined medications have been helpful in some patients. 11, 12 The Research on Asian Prescription Patterns (REAP) is an international collaborative consortium for studying prescription patterns of psychotropic drugs across countries. This consortium has conducted three surveys on antipsychotics (REAP-AP1, -AP2, and -AP3 in 2001, 2004, and 2009, respectively) and two on antidepressants (REAP-AD1 and -AD2 in 2004 and 2013, respectively; http://reap.asia/ index.html). The rate of antipsychotic polypharmacy has been reported in previous surveys. 8, 13 The present study was the fourth REAP survey on antipsychotics (REAP-AP4), and we report herein on the prevalence of antipsychotic polypharmacy and combined medication use across 15 Asian countries and areas.
METHODS

Design and participants
For data collection, this study used an online website-based data key-in system. The research protocol can be accessed at http://reap.asia/reap_ap. html#reap_ap4. In brief, data on the daily medications prescribed for treating inpatients or outpatients with schizophrenia, including antipsychotics, mood stabilizers, antidepressants, anxiolytics, hypnotics, and antiparkinson agents, and demographics were collected. Fifteen Asian countries and areas, namely China, Hong Kong, Japan, South Korea, Singapore, Taiwan (REAP-AP1-3), India, Thailand, Malaysia (REAP-AP3), Bangladesh, Indonesia, Myanmar, Pakistan, Sri Lanka, and Vietnam, participated in this study, which took place between 1 March 2016 and 31 May 2016. Because no established definition of polypharmacy has been reported, 14 here we referred to polypharmacy as the use of two or more antipsychotics, and combined medications as the additional use of other psychotropic drugs in the treatment of schizophrenia. The use of a long-acting injectable antipsychotic combined with the same drug in oral form was considered monotherapy. The prevalence of antipsychotic polypharmacy and combined medications of each psychotropic drug were analyzed.
Conventionally, a chlorpromazine equivalent is used to compare the therapeutic dose of an antipsychotic. [15] [16] [17] Because newer antipsychotics, such as iloperidone, lurasidone, and paliperidone, do not have a chlorpromazine equivalent, 18 the defined daily dose (DDD) system is a useful and reliable tool for international drug utilization studies 19 for comparison with either other antipsychotics alone or combined with other medications. Here, the antipsychotic loading index was calculated using the sum of the prescribed daily dose (PDD) of each antipsychotic, divided by its DDD to indicate the quantity of antipsychotic drugs received by a patient. Accordingly, psychotropic drug loading (PDL) was used to represent the medication quantity prescribed to treat a mental disorder. For schizophrenia, psychotropic drugs comprise five pharmacological classes of drugs, namely antipsychotics, mood stabilizers, antidepressants, anxiolytics, and hypnotics; these drugs are administered to treat the core and peripheral schizophrenia symptoms, such as delusions, hallucinations, agitated or aggressive behaviors, anxious or depressive mood, and insomnia. PDL is the sum of each psychotropic drug's PDD divided by its DDD in the five pharmacological classes. Based on the dose information obtained from the Anatomical Therapeutic Chemical (ATC) Classification System (i.e., the ATC/DDD Index 2016), DDD was considered to be the assumed average maintenance dose per day for a drug used for its main indication in an adult weighing 70 kg (https://www.whocc.no/atc_ddd_index/ [accessed 15 September 2016]). 20 The ATC/DDD system is a tool used for exchanging and comparing data on drug use at international, national, or local levels and has become the gold standard for international drug utilization research. For instance, if a patient receives a daily dose of aripiprazole 15 mg, valproic acid 750 mg, and lorazepam 2 mg, the PDL will be (15/15) + (750/1500) + (2/2.5) = 2.3. We calculated the PDL of each enrolled patient and compared the results between countries.
This REAP-AP4 study was approved by the Institutional Review Board (IRB) of Taipei City Hospital (TCHIRB-10412128-E) for data collection in this hospital and management of all datasets. For remaining regions, IRB approval was obtained from individual study sites.
Statistical analyses
We used SPSS for Windows (version 20; IBM Corp., Armonk, NY, USA) for computing study data. Here, the samples are reported as numbers and percentages as well as means AE SD. A χ 2 -test was then used to compare the four cohorts of the REAP-AP. Statistical significance was set at P < 0.05.
RESULTS
In total, 3744 patients with schizophrenia (1950 inpatients, 1794 outpatients; 2200 men) were enrolled. The numbers and demographics of each country are presented in Table 1 , where countries are listed in order of the number of patients enrolled. The mean age was 39.5 AE 13.1 years, with the oldest patients in Singapore (48.1 AE 13.7 years) and the youngest in Bangladesh (31.9 AE 11.0 years). The mean bodyweight was 62.9 AE 13.8 kg, with the highest patient weights in Hong Kong (71.8 AE 15.4 kg) and the lowest in Bangladesh (52.2 AE 12.4 kg). The mean body mass index was 23.8 AE 4.6. Table 2 shows the numbers and rates of antipsychotic polypharmacy and combined medication use in each country, with the red and blue cells containing more than and less than 1 SD, respectively. The 0%. The mean number of antipsychotics used was 1.5 AE 0.6, with the highest numbers obtained from Japan (1.8 AE 0.9) and the lowest numbers obtained from Myanmar (1.2 AE 0.4). The most used antipsychotic was risperidone (36.9%), followed by olanzapine (20.5%), clozapine (18.5%), haloperidol (15.5%), chlorpromazine (8.4%), quetiapine (7.9%), aripiprazole (5.6%), and trifluoperazine (4.0%).
Notably, there was a large variation in the rates of combined medication use across countries. A comparison of the polypharmacy and drug loading between inpatients and outpatients is outlined in Table 3 . Figure 1 illustrates the comparison of polypharmacy rates across countries, from the REAP-AP1 to REAP-AP4, 8 and Figure 2 depicts the comparison of PDL and antipsychotic loading among the countries. The mean PDL of all patients was 2.01 AE 1.64, with the highest and lowest loadings occurring in Japan (4.1.3 AE 3.13) and Indonesia (1.16 AE 0.68), respectively.
DISCUSSION
The mean rate of antipsychotic polypharmacy in Asian countries was 42.2% (although with considerable variation among the countries), indicating that polypharmacy is still more widely prescribed for Red and blue cells contain more than and less than 1 SD, respectively. DDD, defined daily dose; PDD, prescribed daily dose. .f. = 1; all P < 0.001). In Japan, the use of high doses of antipsychotics and polypharmacy has been conventionally prevalent. 21, 22 To reduce the high rate of polypharmacy, psychotropic dose equivalence has been suggested for dose standardization; in addition, the public insurance reimbursement system, © 2018 The Authors Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology drug reduction program, and pharmacist intervention policies have been revised to improve and prevent psychotropic polypharmacy. [23] [24] [25] Our results indicated that the rate of polypharmacy has reduced in recent years in Japan; nevertheless, among the Asian countries included here, Japan still has the highest average number of antipsychotic use (1.8 AE 0.9) and antipsychotic loading (2. 29 AE 1.79) .
Notably, the rate of polypharmacy increased only in China, from 25 26 The data analysis in that study revealed that polypharmacy-administered patients and their families had lower satisfaction with treatment, higher mental quality of life, earlier onset age, more side-effects, and higher antipsychotic doses; the patients were also more likely to receive first-generation antipsychotics, but less likely to receive benzodiazepines.
The mean antipsychotic loading was 1.50 AE 1.15 in all patients, which was approximately equal to chlorpromazine (DDD, 300 mg) 450 mg/day or risperidone (DDD, 5 mg) 7.5 mg/day. After further stratification (Table 3) , inpatients (n = 1950) showed a significantly higher rate of polypharmacy (49.1%), higher antipsychotic loading, and more psychotropic loading than did outpatients. These differences were attributed to higher illness severity among inpatients. Whether a difference exists between Asian and Western countries in antipsychotic loading should be investigated in future studies.
The large differences in combined medication use observed among countries are difficult to explain. For instance, in Bangladesh, only 1 of 99 (1%) patients was prescribed mood stabilizers; by contrast, 25.8% and 35.0% of the patients in Pakistan and China, respectively, were prescribed mood stabilizers. The rate of antidepressant use was less than 5% in Indonesia, Vietnam, Japan, Myanmar, and Bangladesh, but was 23.4%, 25.8%, and 36.6% in Singapore, Hong Kong, and South Korea, respectively. More than half of the patients in Pakistan (55.7%) and Korea (54.2%) were receiving anxiolytics, whereas this rate was considerably smaller in Myanmar (8.5%) and Sri Lanka (9.3%). However, the most notable difference was observed for the use of hypnotics. In most countries, hypnotics were rarely prescribed, but the rate of their use was 61.1% and 36.5% in Japan and Taiwan, respectively. Nevertheless, our pooled combined medication use rates were lower than those recently reported for 961 patients with schizophrenia from the Eastern European region (anxiolytics, 70%; antidepressants, 42%; mood stabilizers, 27%). 27 Some explanations to account for these differences among countries have been proposed, such as training backgrounds, availability of drugs, and reimbursement systems. Although no guidelines have been established for antipsychotic polypharmacy or combined medications in the treatment of schizophrenia, a subset of patients still requires such unconventional pharmacotherapy. 28 In a special article, 29 polypharmacy and high-dose antipsychotics were proposed. Additional studies are warranted to elucidate the ideal rate of polypharmacy and combined psychotropic drug use.
In this study, we created a PDL index to represent the medication burden on patients with schizophrenia. In the treatment of schizophrenia, we considered each class of drug to have the same weighting, in terms of efficacy and side-effects. This is similar to the disease severity assessment of schizophrenia by the Positive and Negative Syndrome Scale, 30 in which the item of delusion or hallucinatory behavior has the same weighting as the item of anxiety or depression. Notably, Japan had a higher rate of polypharmacy (55.0%) and the highest index of antipsychotic loading (2.29 AE 1.79) and PDL (4.06 AE 3.05); by contrast, Vietnam had the highest rate of polypharmacy (59.1%) and lower antipsychotic loading (1.77 AE 0.96) and PDL (2.09 AE 1.11). This example reveals that a high rate of polypharmacy does not necessarily indicate a high burden of psychotropic drugs. Thus, when reviewing a prescription pattern in the treatment of schizophrenia, the evaluation of antipsychotic polypharmacy rate, antipsychotic loading index, and global PDL is crucial.
The PDL index may be applied to any other psychiatric disorder; the concept of drug loading may also be applied to other diseases, such as hypertension and diabetic mellitus, where polypharmacy or combined medication use is prevalent.
The main perspectives of the REAP are comparing the differences in prescription patterns across Asian countries and contributing to the improvement of psychotropic drug prescription quality in the Asian countries that participate in this collaborative consortium. Similar to the conception of a quality indicator project, 31 ,32 a set of indicators can be developed by using these comparisons; the exact positions of these indicators can then be learned by clinicians and health administrators to obtain consistent results. Thus, according to the REAP-AP4 data related to schizophrenia pharmacotherapy in Asian countries, we suggest the ideal rate of antipsychotic polypharmacy could be around 30%; the approximate rates in combination with mood stabilizers, antidepressants, anxiolytics, and hypnotics could be 15%, 10%, 30%, and 10%, respectively; furthermore, the antipsychotic loading and PDL could be approximately 1.5 and 2.0, respectively.
In conclusion, the differences in prescription patterns in the treatment of schizophrenia among countries and fluctuations in the results among the REAP-AP1-4 may attribute to the diverse training backgrounds of psychiatrists, civil culture, availability and cost of drugs, patient characteristics, and the local health-care reimbursement system of each country. For a prescriber treating schizophrenia, the golden rule should be an adequate dose of antipsychotic, reducing polypharmacy and combined medication as much as possible. The results from all of the REAP-AP studies provide a basis to compare individual clinicians and countries, facilitating a more suitable and reasonable prescription pattern. They also offer an indicator of change of practice due to changes in the education of psychiatry and other mental health system interventions.
Limitations
This study had several limitations, as follows: the convenient sampling method may have incurred selection bias; patients underwent antipsychotic switching and dose tapering; the numbers of patients enrolled from each country varied; no stratification of illness severity was performed; and the sample was ethnically diverse. Nevertheless, the comparison of the four surveys may approximate trends of antipsychotic polypharmacy and combined medications in the treatment of patients with schizophrenia across Asian countries. Future research should employ a more precise study design, and also investigate the effects of prescription patterns on bipolar disorder or other minor psychiatric disorders, particularly by comparing them with results from Western countries.
